Physician profile
Andrew Kwait
NPI 1700925823
$81,802.31
in general payments reported to CMS, 2019-2025
11 companies · $11K in 2025
The $11K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $9,202 · 2021: $4,371 · 2022: $7,539 · 2023: $9,714 · 2024: $11K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $1,633 · Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,512.50 |
| Travel and Lodging | $1,633.23 |
| Food and Beverage | $1,252.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $68,407.98 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $8,661.34 | 2020-2022 | |
| Indivior INC. | $4,225.88 | 2019-2020 | |
| Shire North American Group INC | $161.17 | 2019 | |
| Janssen Scientific Affairs, LLC | $93.83 | 2019-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $82.73 | 2019 | |
| Alkermes, INC. | $57.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.94 | 2020 | |
| Sunovion Pharmaceuticals INC. | $26.17 | 2021 | |
| Glaxosmithkline, LLC. | $21.06 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kwait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.